相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。JAK3 inhibitors based on thieno[3,2-d]pyrimidine scaffold: design, synthesis and bioactivity evaluation for the treatment of B-cell lymphoma
Fuyun Chi et al.
BIOORGANIC CHEMISTRY (2020)
Design, synthesis, and pharmacological evaluation of 4-or 6-phenyl-pyrimidine derivatives as novel and selective Janus kinase 3 inhibitors
Lei Shu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Alkynyl Benzoxazines and Dihydroquinazolines as Cysteine Targeting Covalent Warheads and Their Application in Identification of Selective Irreversible Kinase Inhibitors
Kirsten McAulay et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2020)
Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Michael F. Robinson et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Loss of Mef2D function enhances TLR induced IL-10 production in macrophages
Michael J. Pattison et al.
BIOSCIENCE REPORTS (2020)
Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) Inhibitors
Jun Dai et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2019)
JAK inhibitors for the treatment of autoimmune and inflammatory diseases
Yvan Jamilloux et al.
AUTOIMMUNITY REVIEWS (2019)
Differential control of Toll-like receptor 4-induced interleukin-10 induction in macrophages and B cells reveals a role for p90 ribosomal S6 kinases
Ruhcha V. Sutavani et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Development, Optimization, and Structure-Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4-d]pyrrolo[2,3-b]pyridine Scaffold
Michael Forster et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
FDA approves Eli Lilly's baricitinib
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2018)
Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-(2s,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-y1)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans
Atli Thorarensen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Daniella M. Schwartz et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting
Michael Forster et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Mechanisms and consequences of Jak-STAT signaling in the immune system
Alejandro V. Villarino et al.
NATURE IMMUNOLOGY (2017)
Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition
Jean-Baptiste Telliez et al.
ACS CHEMICAL BIOLOGY (2016)
Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling
Geoffrey A. Smith et al.
NATURE CHEMICAL BIOLOGY (2016)
Dimethyl fumarate blocks proinflammatory cytokine production via inhibition of TLR induced M1 and K63 ubiquitin chain formation
Victoria A. McGuire et al.
SCIENTIFIC REPORTS (2016)
Commentary: IL-4 and IL-13 receptors and signaling
Sarah M. McCormick et al.
CYTOKINE (2015)
Development of Selective Covalent Janus Kinase 3 Inhibitors
Li Tan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Tricyclic Covalent Inhibitors Selectively Target Jak3 through an Active Site Thiol
Eric R. Goedken et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
ATP-Mediated Kinome Selectivity: The Missing Link in Understanding the Contribution of Individual JAK Kinase Isoforms to Cellular Signaling
Atli Thorarensen et al.
ACS CHEMICAL BIOLOGY (2014)
Selective inhibitors of the Janus kinase Jak3-Are they effective?
Gebhard Thoma et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
Qingsong Liu et al.
CHEMISTRY & BIOLOGY (2013)
Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market
Ken Garber
NATURE BIOTECHNOLOGY (2013)
Inborn Errors of Human JAKs and STATs
Jean-Laurent Casanova et al.
IMMUNITY (2012)
Inhibition of JAKs in Macrophages Increases Lipopolysaccharide-Induced Cytokine Production by Blocking IL-10-Mediated Feedback
Michael J. Pattison et al.
JOURNAL OF IMMUNOLOGY (2012)
JAK3 Specific Kinase Inhibitors: When Specificity Is Not Enough
Luk Cox et al.
CHEMISTRY & BIOLOGY (2011)
Jak1 Has a Dominant Role over Jak3 in Signal Transduction through γc-Containing Cytokine Receptors
Claude Haan et al.
CHEMISTRY & BIOLOGY (2011)
Identification of a Potent Janus Kinase 3 Inhibitor with High Selectivity within the Janus Kinase Family
Gebhard Thoma et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
Alfonso Quintas-Cardama et al.
BLOOD (2010)
A Chemical Genetic Approach Reveals That p38α MAPK Activation by Diphosphorylation Aggravates Myocardial Infarction and Is Prevented by the Direct Binding of SB203580
Sarawut Kumphune et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
The selectivity of protein kinase inhibitors: a further update
Jenny Bain et al.
BIOCHEMICAL JOURNAL (2007)
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
Ross L. Levine et al.
NATURE REVIEWS CANCER (2007)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A chemical switch for inhibitor-sensitive alleles of any protein kinase
AC Bishop et al.
NATURE (2000)
分享论文
